ArticleBiomedical optics express2026
Fluorescent properties of FDA-approved anti-leukemia drugs.
Article in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inherent fluorescent properties of anti-leukemic drugs offer unique advantages for real-time therapeutic tracking and optimization. In this study, we systematically screened the absorption and emission spectra of 82 leukemia-related compounds, identifying 28 autofluorescent drugs suitable for fluorescence-based optical concentration monitoring. Excitation and emission parameters were evaluated across various solvents (DMSO, fetal bovine serum, and culture media), revealing solvent-dependent spectral changes, intensity variations, and effect on detection limits. These 28 compounds were further assessed for cytotoxicity screening in case of drug-naive and drug-resistant K562 leukemia lymphoblast cells. By correlating their spectral properties with cytotoxic responses, our study establishes a robust framework for fluorescence-assisted drug profiling, enabling pharmacokinetic insights, resistance prediction, and informed therapeutic adjustments. These findings underscore the translational potential of fluorescence-based methodologies in supporting precision medicine for leukemia treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.